- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01339273
Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection
Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection- a Double Blind Randomised Controlled Trial
Laparoscopic (key-hole) large bowel resection is a minimally invasive procedure when compared to open large bowel resection, but is still associated with a significant amount of pain and discomfort. Analgesia is commonly provided by a multi-modal technique involving varying combinations of paracetamol, Non steroidal anti-inflammatory drugs (NSAIDs), regional analgesia and oral or parenteral opioids. While epidural analgesia is considered the gold standard for open colo-rectal procedures it can be associated with significant complications and may delay hospital discharge in laparoscopic procedures. Opioids are associated with an increased incidence of nausea, vomiting and sedation and reduced bowel motility which can also prolong recovery.
Transversus Abdominis Plane (TAP) block is a technique which numbs the nerves carrying pain sensation from the abdominal wall and provides effective and safe analgesia with minimal systemic side effects. Their perceived benefits are thought to relate to reduced opioid consumption and therefore reduced opioid side effects. The investigators believe ultrasound guided TAP blocks will reduce pain and morphine consumption with a resultant improved patient satisfaction, earlier return of bowel function and earlier hospital discharge.
The key research question the investigators are trying to answer is whether TAP block provide better pain relief than local anaesthetic infiltration of the laparoscopic port sites. Both techniques are currently being used in our hospital and a retrospective audit demonstrated better analgesia and lower consumption of morphine in the TAP block group.The differences were not statistically significant as the number patients in the audit were not large enough.The investigators are hoping that this study will demonstrate that the difference is real by recruiting the necessary number of patients into each group (36 per group)
Study Overview
Status
Detailed Description
Summary of Study Design The study will be a double blind randomised controlled trial with patients undergoing laparoscopic right hemicolectomy or laparoscopic high anterior resection randomly allocated into two groups, with the study group receiving bilateral TAP blocks followed by a morphine PCA and the control group receiving local anaesthetic infiltration of the laparoscopic port sites and specimen extraction site and a morphine PCA.
A double blind design was chosen to eliminate patient and observer bias in reporting of pain scores.
The presence of the control arm will ensure that any difference observed will be due to the effect of sensory nerve block due to the TAP block than due to the systemic effect of the injected local anaesthetic.
The null hypothesis will be that there is no difference between the groups in the amount of morphine consumed by the patients during 48 hours after the operation. We chose this measurement as an objective but indirect measurement of efficacy of TAP block and pain relief thus received. Measurement of pain with various scoring methods are reliable only when concurrent reduction in consumption of pain killers are demonstrated.
Recruitment and randomisation:
All patients meeting the inclusion criteria will receive a patient information leaflet and an invitation letter to participate in the study during the pre-assessment visit. We aim to recruit 72 patients (36 patients per group).
Informed consent will be taken by one of the investigators on the morning of the surgery, if the exclusion criteria are not applicable. Patients will be allotted consecutive participant numbers starting from one. Patients will be randomly allocated into either the study group and a control group. Randomisation will occur by using computer generated random numbers. Group allocation will be kept in a consecutively numbered, opaque, sealed envelope in the controlled drugs cupboard in theatre-6 anaesthetic room of Churchill hospital.Once patient has consented, the anaesthetist will open the corresponding numbered envelope and perform bilateral TAP blocks after induction of general anaesthesia, if the patient is in the study group the surgeons will infiltrate the port sites with local anaesthetic at the end of the procedure if the patient is in the control group.
Blinding:
The study group will receive bilateral TAP blocks with 20mls 0.25% bupivacaine on each side and the skin punctures on either sides will be covered with a small plaster. Patients in the control group will receive subcutaneous infiltration of the laparoscopic port sites and specimen extraction site with equivalent amount bupivacaine at the end of the procedure and small plasters will be stuck on either flanks approximately where the skin punctures for TAP block will be made.
The assessor of pain scores and morphine doses (Recovery nurse & Colo-rectal house officer) and the patient will be blinded to group allocation.
Patient: Plasters will be stuck on flanks of all the patients both study and control group so that patient will not know if they have received TAP block.
Recovery nurse: During handover to recovery the anaesthetist and scrub nurse will not mention about group allocation.
Colo-rectal house officer: The house officers( Junior Doctors) who will be following up in the ward will not present in the operating theatre, so they will be blinded
The study duration will be from induction of anaesthesia until the patients are medically fit for discharge from hospital. No extra visits other than routinely required for the surgical procedure is expected.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 9DU
- The Churchill Hospital, Oxford Radcliffe Hospitals NHS trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Undergoing elective laparoscopic high anterior resection without stoma or laparoscopic right hemicolectomy.
- American Society of Anaesthetists physical status (ASA) 1-3
Exclusion Criteria:
- Opioid tolerance
- Chronic abdominal pain
- Allergy/Intolerance: Morphine, local anaesthetics
- BMI>35 Kg/M2
- Previous major abdominal surgery
- High likelihood of conversion to open procedure
- Patients unable to communicate in written and spoken English
- Weight less than 50 kg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TAP block
Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
|
Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
|
|
Active Comparator: Local anaesthetic infiltration
Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
|
Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Morphine Consumption in the First 48hours After the Operation
Time Frame: 48 hours after the operation
|
Total morphine consumption in the first 48 hours after the surgery will be calculated from the drug chart and the Patient controlled analgesia(PCA)pump.
|
48 hours after the operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numerical Rating Pain Scores at 48 Hours Postoperatively
Time Frame: 48 hours after the operation
|
Numerical Rating Scores for Pain (0-10) 0= no pain 10= severe pain
|
48 hours after the operation
|
|
Nausea Score at 48 Hours Postoperatively
Time Frame: 48 hours after the operation
|
0-10 0= no nausea 10=severe nausea
|
48 hours after the operation
|
|
Time to First Request for Rescue Analgesia
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
The time will be calculated from the drug chart looking up when the first dose of rescue morphine was administered
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Time to Mobilisation
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
Time will be calculated from the nursing notes and patient diary, when the patient was first mobilised.
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Time to Successful Intake of Fluids
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
Time will be calculated from the nursing notes and patient diary, when the patient had first successful intake of oral fluids.
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Time to Resumption of Normal Diet
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
Time will be calculated from the nursing notes and patient diary, when the patient resumed normal diet.
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Time to First Bowel Motion
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
Time will be calculated from the nursing notes and patient diary, when the patient had the first bowel motion.
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Time to First Flatus
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
Time will be calculated from the nursing notes and patient diary, when the patient first passed flatus.
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Time to Medically Fit to Discharge
Time Frame: After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
Time will be calculated from the medical notes, when the decision that the patient is medically fit to be discharged was made.
|
After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days.
|
|
Total Morphine Consumption at 24hours
Time Frame: 24 hours
|
24 hours
|
|
|
Nausea at 24hours Post Operatively
Time Frame: 24 hours
|
24 hours
|
|
|
Time to Mobilization
Time Frame: days
|
days
|
|
|
Time to Hospital Discharge
Time Frame: days
|
days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nicholas Crabtree, MB,ChB, FRCA, Nuffield Department of Anaesthetics, Oxford Radcliffe Hospitals NHS Trust , Oxford
Publications and helpful links
General Publications
- McDonnell JG, O'Donnell B, Curley G, Heffernan A, Power C, Laffey JG. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial. Anesth Analg. 2007 Jan;104(1):193-7. doi: 10.1213/01.ane.0000250223.49963.0f. Erratum In: Anesth Analg. 2007 May;104(5):1108.
- McDonnell JG, O'Donnell BD, Farrell T, Gough N, Tuite D, Power C, Laffey JG. Transversus abdominis plane block: a cadaveric and radiological evaluation. Reg Anesth Pain Med. 2007 Sep-Oct;32(5):399-404. doi: 10.1016/j.rapm.2007.03.011.
- El-Dawlatly AA, Turkistani A, Kettner SC, Machata AM, Delvi MB, Thallaj A, Kapral S, Marhofer P. Ultrasound-guided transversus abdominis plane block: description of a new technique and comparison with conventional systemic analgesia during laparoscopic cholecystectomy. Br J Anaesth. 2009 Jun;102(6):763-7. doi: 10.1093/bja/aep067. Epub 2009 Apr 17. Erratum In: Br J Anaesth. 2009 Oct;103(4):622.
- Zafar N, Davies R, Greenslade GL, Dixon AR. The evolution of analgesia in an 'accelerated' recovery programme for resectional laparoscopic colorectal surgery with anastomosis. Colorectal Dis. 2010 Feb;12(2):119-24. doi: 10.1111/j.1463-1318.2009.01768.x. Epub 2009 Jan 16.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Pathological Conditions, Anatomical
- Intestinal Neoplasms
- Colorectal Neoplasms
- Diverticular Diseases
- Colonic Neoplasms
- Diverticulum
- Diverticulosis, Colonic
- Diverticulum, Colon
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anesthetics, Local
Other Study ID Numbers
- Sponsorship review number:113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
First Affiliated Hospital of Wenzhou Medical UniversityCompletedRectal Cancer Stage | Rectal Cancer PatientsChina
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.Active, not recruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
Clinical Trials on Ultrasound guided Transversus Abdominis Plane (TAP) bock
-
Nordsjaellands HospitalCompletedPostoperative PainDenmark
-
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training...Maltepe UniversityCompletedPostoperative Pain ManagementTurkey (Türkiye)
-
Aretaieion University HospitalEnrolling by invitationPerioperative Pain in Robotic ProstatectomyGreece
-
Sanliurfa Education and Research HospitalNot yet recruitingSleeve Gastrectomy | External Oblique Intercostal Plane Block | Subcostal Transverse Abdominis Plane BlockTurkey (Türkiye)
-
Tribhuvan University Teaching Hospital, Institute...Not yet recruiting
-
Samsun UniversityCompletedCaesarean Section | Acute Pain ManagementTurkey
-
Ankara Ataturk Sanatorium Training and Research...RecruitingPostoperative Pain | Erector Spinae Plane Block | Abdominoplasty | Transversus Abdominis Plane (TAP) BlockTurkey
-
Oxford University Hospitals NHS TrustWithdrawn
-
Cukurova UniversityRecruiting
-
Helwan UniversityCompletedTransversus Abdominis Plane Block | Herniorrhaphy | Spinal AnaesthesiaEgypt